Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.<ref name="insert">[https:// | + | Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe Cladribine package insert]</ref><ref>[[Media:Cladribine.pdf | Cladribine (Leustatin) package insert (locally hosted backup)]]</ref> |
<br>Route: IV, SC | <br>Route: IV, SC | ||
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference | <br>Extravasation: [[irritant]] or [[neutral]], depending on reference | ||
| Line 18: | Line 18: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https:// | + | *[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe Cladribine package insert]<ref name="insert"></ref> |
*[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | ||
Revision as of 17:12, 27 May 2021
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV, SC
Extravasation: irritant or neutral, depending on reference
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Hairy cell leukemia
- Hypereosinophilic syndrome
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Systemic mastocytosis
- Waldenström macroglobulinemia
Patient drug information
- Cladribine package insert[1]
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/26/1993: Initial FDA approval for treatment of active hairy cell leukemia
Also known as
- Generic names: 2-chlorodeoxyadenosine, 2-CdA
- Brand names: Leustatin, Litak, Movectro
References
Categories:
- Drugs
- Intravenous medications
- Subcutaneous medications
- Irritant
- Neutral
- Antimetabolites
- Purine analogues
- Acute myeloid leukemia medications
- Chronic lymphocytic leukemia medications
- Hairy cell leukemia medications
- Hypereosinophilic syndrome medications
- Langerhans cell histiocytosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Systemic mastocytosis medications
- Waldenström macroglobulinemia medications
- FDA approved in 1993